Infectious Skin Diseases: A Review and Needs Assessment

Dawson, Annelise L.; Dellavalle, Robert P.; Elston, Dirk M.

doi:10.1016/j.det.2011.08.003

Cited by 29 publications

(15 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, skin tumors (benign and malignant) are basically derived from hair follicles and might represent a further concerning issue. Chronic inflammatory skin diseases such as psoriasis, atopic dermatitis and allergic contact dermatitis are the combined result of infiltration of inflammatory T cells with increased production of cytokines in the lesions (schematic representation shown in Figure 1) [3].…”

Section: Introductionmentioning

confidence: 99%

Nanocarrier-based topical drug delivery for the treatment of skin diseases

Gupta

Agrawal

Vyas

2012

Expert Opinion on Drug Delivery

211

View full text Add to dashboard Cite

Skin-targeted topical delivery by means of nanosystems, in order to produce sustained release and maintain a localized effect, will result in an effective treatment of various life-threatening dermatological conditions. In addition, research continues into the interactions between novel particles, skin and skin lipid, and the influence of particle composition on drug distribution within the skin strata.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanocarrier-based topical drug delivery for the treatment of skin diseases

Gupta

Agrawal

Vyas

2012

Expert Opinion on Drug Delivery

211

View full text Add to dashboard Cite

show abstract

“…Fungal infections are very common and upon exposure they are also contagious. These infections are estimated to affect more than 20% of the world's population [1]. It occurs frequently in population where common living facilities are used.…”

Section: Resultsmentioning

confidence: 99%

“…Griseofulvin, terbinafine, and azoles such as fluconazole, itraconazole, and ketoconazole are the most widely used systemic antifungal therapies for cutaneous fungal infections. The use of these agents can result in drug toxicities for which monitoring of hepatic and renal functions are required [1]. Patients generally look for inexpensive and rapid recovery resolution for cutaneous type of infection.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Topical Delivery of Lipid Based Amphotericin B Gel in the Treatment of Fungal Infection: A Clinical Efficacy, Safety and Tolerability Study in Patients

Ahmad¹

2014

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Objectives: A novel topical formulation of lipid based amphotericin B (0.1% amphotericin B Gel) was developed to assess the safety, tolerability and efficacy in adult patients with cutaneous and/or mucocutaneous fungal infection. Methods: Amphotericin B gel was formulated using lipids. In vitro release assay of amphotericin B was measured using paddle apparatus maintained at 37.0° ± 0.5°C. The stability studies of amphotericin B gel were carried out at 2-8°C, 25°C and 40°C. To test the effect of the drug in clinical setting, 100 patients with recurrent case after failure to standard therapy for cutaneous and/or mucocutaneous fungal infection were treated with amphotericin B Gel. The amphotericin B Gel was applied on the affected area twice daily for 14 days in patients with cutaneous fungal infection and for 7 days in patients of mucocutaneous fungal infection. Response to the amphotericin B Gel treatment was monitored in the patients for up to 14 days and 28 days for mucocutaneous and cutaneous infection respectively. Results: Based on the stability studies, the recommended shelf life of amphotericin B gel is 24 months at 25°C. In vitro studies showed the release of ~90% amphotericin B within two hours and complete release within four hours. A total of 83 patients were assessed for cutaneous fungal infection where 39 patients were cured, 9 patients showed marked improvement, 26 patients showed moderate improvement and 9 patients showed failure after the treatment. For mucocutaneous fungal infection, 100% patients were cured at the end of the treatment. No serious adverse events were reported in patients during the study. Conclusion: Lipid based amphotericin B gel in patients with cutaneous and mucocutaneous fungal infections was found to be safe, tolerable and efficacious.

show abstract

“…Viral skin infections (VSIs) were ranked among the top 50 prevalent diseases in 2010 with a global prevalence of 122,601,000 [1]. Common VSIs include herpes simplex (HS), herpes zoster (HZ), molluscum contagiosum (MC), anogenital warts, and viral warts [2]. Geographically representative data, on the periodic evaluation of epidemiology of VSIs, are important from clinical and public health perspectives.…”

Section: Introductionmentioning

confidence: 99%

Epidemiologic Trends of Viral Skin Infections in Egypt: A Cross-Sectional Hospital-Based Study

Saleh

Nada

Hamed

et al. 2019

Dermatology Research and Practice

View full text Add to dashboard Cite

Viral skin infections (VSIs) were ranked among the top 50 prevalent diseases in 2010. The objective of this study was to determine the epidemiologic features of VSIs in patients attending a dermatology clinic in Egypt from June 2010 to May 2011. Patient’s residence, occupation, housing data, and family history of similar conditions were recorded. Categorical data were recorded as frequencies and percentages and were compared by Chi square test. P value < 0.05 was significant. Diagnosis of VSIs was made in 1000/20322 (4.9%) patients. Out of the 1000 patients with VSIs, 580 (58.0%) were residents of rural areas and 420 (42.0%) were residents of urban areas (p = 0.02). Out of the 1000 patients, 489 (48.9%) were females and 511 (51.1%) were males (p = 0.25). The breakdown of 1000 patients with VSIs indicated diagnosis of viral warts in 673 (67.3%), chickenpox (CP) in 200 (20.0%), herpes simplex (HS) facialis in 50 (5.0%), herpes zoster (HZ) in 42 (4.2%), molluscum contagiosum (MC) in 27 (2.7%.0), and anogenital warts in 8 (0.8%) cases. Overcrowding (sharing a bedroom by more than 3 persons) was recorded in 652/1000 (65.2%) of the patients with VSIs [165/200 (82.5.3%) in CP, 36/50 (72%) in HS facials, 427/673 (63.4%) in viral warts, 14/27 (51.9%) in MC, and 10/42 (23.8%) in HZ]. Family history of a similar condition was positive in 329/1000 (32.9%) of the patients with VSIs [142/200 (71.0%) in CP, 177/673 (26.3%) in viral warts, 5/27 (18.5%) in MC, and 4/50 (8%) in HS facialis]. In conclusion, viral warts and CP were the commonest VSIs diagnosed in patients who attended a dermatology clinic in Egypt. Viral skin infections were more prevalent among patients who lived in rural areas and under crowded conditions. These data may have important public health implications particularly in developing countries.

show abstract

Infectious Skin Diseases: A Review and Needs Assessment

Cited by 29 publications

References 91 publications

Nanocarrier-based topical drug delivery for the treatment of skin diseases

Nanocarrier-based topical drug delivery for the treatment of skin diseases

Topical Delivery of Lipid Based Amphotericin B Gel in the Treatment of Fungal Infection: A Clinical Efficacy, Safety and Tolerability Study in Patients

Epidemiologic Trends of Viral Skin Infections in Egypt: A Cross-Sectional Hospital-Based Study

Contact Info

Product

Resources

About